Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Other Non Operating Income (2016 - 2026)

Integra Lifesciences Holdings' Other Non Operating Income history spans 17 years, with the latest figure at $581000.0 for Q4 2025.

  • On a quarterly basis, Other Non Operating Income fell 42.19% to $581000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.4 million, a 159.61% decrease, with the full-year FY2025 number at -$2.4 million, down 159.61% from a year prior.
  • Other Non Operating Income hit $581000.0 in Q4 2025 for Integra Lifesciences Holdings, up from -$842000.0 in the prior quarter.
  • Over the last five years, Other Non Operating Income for IART hit a ceiling of $5.0 million in Q2 2021 and a floor of -$1.9 million in Q2 2025.
  • Historically, Other Non Operating Income has averaged $1.8 million across 5 years, with a median of $1.7 million in 2022.
  • Biggest five-year swings in Other Non Operating Income: skyrocketed 1116.49% in 2021 and later plummeted 235.42% in 2025.
  • Tracing IART's Other Non Operating Income over 5 years: stood at $4.4 million in 2021, then decreased by 10.59% to $4.0 million in 2022, then crashed by 49.05% to $2.0 million in 2023, then plummeted by 50.07% to $1.0 million in 2024, then plummeted by 42.19% to $581000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for IART at $581000.0 in Q4 2025, -$842000.0 in Q3 2025, and -$1.9 million in Q2 2025.